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In the main article, we have described our approach which we refer to as thermodynamic
integration with enhanced sampling (TIES) to rapidly calculate accurate, precise and repro-
ducible relative binding affinities of ligand-protein complexes. All our results along with the
quantification of their accuracy and precision are detailed there. In the Supporting Infor-
mation, we provide additional details for our results. Figures S1 to S5 shows the chemical
structures and experimental binding affinities of all the ligands used in our calculations for
the five target proteins. The structures are downloaded from the Supporting Information
of an open access article.S1 The experimental binding affinities for thrombin are taken from
the reported ITC experiments,S2 while for other targets they are calculated with equation
1 using the reported IC50 or Ki values.S3–S7 Tables S1 to S5 provide the predicted and ex-
perimental ∆∆G values for all the 55 transformations studied, while Figure S6 shows the
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correlation between TIES-predictions and the experimental data for each biomolecular sys-
tem separately. The ∆∆GTIES and σTIES are calculated as described in Section 3.3 of the
main article.
∆Gexp = RT lnKi
∆Gexp ≈ RT ln(IC50)
(1)
where T=297 K and R is the gas constant.Figure S7 shows the variation of the mean energy
derivative with the simulation length for one of the transformations studied providing a
justification to our choice of 2 ns long equilibration phase. Thereafter, we provide a more
detailed discussion of selected ligand-protein interactions of note. In particular, we discuss
how to compute relative binding affinities in situations where there is a significant change in
the charge distribution within the pair of ligands studied. Figure S10 displays a comparison
of the relative binding affinity predictions from TIES with those from Wang et al. using
FEP methodS1 for the 18 transformations found common in both the studies. Table S6 lists
the set of ligands forming closed cycles in the transformations studied and the corresponding
values of hysteresis. Figure S11 shows the variation of the uncertainties in TIES-predictions
with the size of perturbation for the transformations in ligands binding with PTP1B.
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L1Q; ∆Gexp=-8.18 LI9; ∆Gexp=-9.74 L17; ∆Gexp=-7.04 L20; ∆Gexp=-8.72
L21; ∆Gexp=-7.83 L26; ∆Gexp=-8.43 L29; ∆Gexp=-9.88
Figure S1: Chemical structures and experimental binding affinities (kcal/mol) of
CDK2 ligands. No errors are available on the values used in this study as quoted
above.
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L1; ∆Gexp=-8.24 L2; ∆Gexp=-6.66 L3; ∆Gexp=-6.88
L4; ∆Gexp=-7.60 L5; ∆Gexp=-8.81 L6; ∆Gexp=-7.92
L8; ∆Gexp=-7.69 L9; ∆Gexp=-6.58 L12; ∆Gexp=-9.33
Figure S2: Chemical structures and experimental binding affinities (kcal/mol) of
MCL1 ligands. No errors are available on the values used in this study as quoted
above.
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L13; ∆Gexp=-6.62 L16; ∆Gexp=-8.95 L17; ∆Gexp=-7.85
L18; ∆Gexp=-9.78 L32; ∆Gexp=-5.78 L34; ∆Gexp=-9.26
L35; ∆Gexp=-9.96 L38; ∆Gexp=-8.95 L39; ∆Gexp=-8.90
Figure S2: Chemical structures and experimental binding affinities (kcal/mol) of
MCL1 ligands (continued). No errors are available on the values used in this
study as quoted above.
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L41; ∆Gexp=-6.87 L42; ∆Gexp=-7.03
Figure S2: Chemical structures and experimental binding affinities (kcal/mol) of
MCL1 ligands (continued). No errors are available on the values used in this
study as quoted above.
L1; ∆Gexp=-8.46 L2; ∆Gexp=-8.25 L3; ∆Gexp=-7.86
Figure S3: Chemical structures and experimental binding affinities (kcal/mol) of
thrombin ligands. No errors are available on the values used in this study as
quoted above.
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L4; ∆Gexp=-7.48 L5; ∆Gexp=-9.18 L6; ∆Gexp=-8.22
L7; ∆Gexp=-8.32 L8; ∆Gexp=-7.58 L9; ∆Gexp=-8.89
L10; ∆Gexp=-8.91 L11; ∆Gexp=-8.56
Figure S3: Chemical structures and experimental binding affinities (kcal/mol) of
thrombin ligands (continued). No errors are available on the values used in this
study as quoted above.
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L1; ∆Gexp=-7.72 L2; ∆Gexp=-8.65 L3; ∆Gexp=-9.11
L4; ∆Gexp=-8.72 L6; ∆Gexp=-12.47 L7; ∆Gexp=-8.61
L8; ∆Gexp=-10.01 L10; ∆Gexp=-8.39 L11; ∆Gexp=-9.08
Figure S4: Chemical structures and experimental binding affinities (kcal/mol) of
PTP1B ligands. No errors are available on the values used in this study as
quoted above.
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L12; ∆Gexp=-7.75 L13; ∆Gexp=-8.72 L14; ∆Gexp=-11.42
L19; ∆Gexp=-7.85 L20; ∆Gexp=-9.41 L22; ∆Gexp=-9.14
L23; ∆Gexp=-10.12
Figure S4: Chemical structures and experimental binding affinities (kcal/mol) of
PTP1B ligands (continued). No errors are available on the values used in this
study as quoted above.
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L1; ∆Gexp=-9.54 L3; ∆Gexp=-8.98 L5; ∆Gexp=-9.21
L6; ∆Gexp=-8.26 L8; ∆Gexp=-7.75 L10; ∆Gexp=-7.42
L11; ∆Gexp=-11.28 L15; ∆Gexp=-9.78 L16; ∆Gexp=-10.53
Figure S5: Chemical structures and experimental binding affinities (kcal/mol) of
TYK2 ligands. No errors are available on the values used in this study as quoted
above.
S10
Table S1: ∆∆GTIES for CDK2. All values are in kcal/mol. No errors are available on the
experimental data.
Transformation ∆∆GTIES σTIES ∆∆Gexp
L1Q-LI9 1.96 0.26 1.56
L1Q-L20 0.59 0.23 0.54
L1Q-L21 -1.33 0.15 -0.35
L20-L21 -1.90 0.26 -0.89
L1Q-L26 1.20 0.19 0.25
L1Q-L29 2.49 0.25 1.70
L1Q-L17 -0.17 0.16 -1.14
Table S2: ∆∆GTIES for MCL1. All values are in kcal/mol. No errors are available on the
experimental data.
Transformation ∆∆GTIES σTIES ∆∆Gexp
L2-L4 2.97 0.31 0.94
L6-L41 -0.03 0.23 -1.05
L3-L5 1.21 0.21 1.93
L3-L16 2.92 0.17 2.07
L16-L34 -0.33 0.69 0.31
L12-L35 2.57 0.82 0.63
L2-L32 1.77 0.26 -0.88
L32-L42 1.45 0.37 1.25
L38-L42 -3.33 0.29 -1.92
L32-L38 3.59 0.33 3.17
L39-L42 -2.40 0.21 -1.87
L18-L39 -3.50 0.71 -0.88
L1-L8 0.09 0.79 -0.55
L8-L18 3.83 0.69 2.09
L17-L9 -0.17 0.24 -1.27
L13-L17 0.60 0.32 1.23
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Table S3: ∆∆GTIES for thrombin. All values are in kcal/mol. No errors are available on
the experimental data.
Transformation ∆∆GTIES σTIES ∆∆Gexp
L8-L1 1.04 0.24 0.88
L1-L8 -0.61 0.24 -0.88
L6-L7 -0.48 0.26 0.10
L3-L5 2.25 0.23 1.32
L5-L6 -2.12 0.21 -0.96
L1-L4 -1.75 0.35 -0.98
L2-L5 0.38 0.23 0.93
L4-L11 2.18 0.28 1.08
L7-L3 0.41 0.27 -0.46
L1-L9 1.08 0.25 0.43
L4-L10 2.42 0.24 1.43
Table S4: ∆∆GTIES for TYK2. All values are in kcal/mol. No errors are available on the
experimental data.
Transformation ∆∆GTIES σTIES ∆∆Gexp
L1-L3 0.11 0.07 -0.56
L1-L6 -1.38 0.09 -1.28
L6-L11 2.28 0.28 3.02
L6-L10 -1.15 0.14 -0.84
L15-L16 1.08 0.21 0.75
L1-L8 -0.94 0.08 -1.79
L5-L16 0.19 0.16 1.32
L1-L15 0.07 0.06 -0.33
L15-L6 -1.51 0.09 -1.52
L1-L10 -2.21 0.21 -2.12
L15-L10 -2.59 0.10 -2.36
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Table S5: ∆∆GTIES for PTP1B. All values are in kcal/mol. No errors are available on the
experimental data.
Transformation ∆∆GTIES σTIES ∆∆Gexp
L1-L2 1.54 0.33 0.93
L10-L12 -0.14 0.51 -0.64
L19-L3 1.19 0.29 1.26
L3-L7 0.04 0.15 -0.50
L3-L23 0.80 0.32 1.01
L11-L23 1.54 0.15 1.04
L13-L20 0.68 0.24 0.69
L6-L14 -0.81 0.44 -1.05
L8-L14 1.40 0.34 1.41
L4-L22 -0.61 0.23 0.42
Figure S6: Correlation between TIES-predicted binding affinities and the experimental data
for each biomolecular system shown separately. The uncertainties in the TIES predictions
are included as error bars. The dashed line is the regression line in each case.
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Figure S7: Variation of 〈∂V/∂λ〉 with the simulation length (including both equilibration
and production phases) for all five replicas at four different λ windows in the case of the
transformation from ligand L1 to L4 binding to thrombin. It is clearly visible that all replicas
converge at about 2 ns which is the length of the equilibration run in our existing protocol.
The variation in the final converged values of 〈∂V/∂λ〉 for different replicas at a given λ
window as shown above emphasises the advantage of performing ensemble simulation.
Discussion of selected ligand-protein interactions
As noted in the main text in the intermediate λ-windows of TIES calculations the elec-
trostatic interactions are weakly scaled which can result in larger fluctuations of ∂V/∂λ (due
to loss or gain of strong electrostatic interactions). This results in larger variation in the
stochastic integral (equation 2 in the main article) and hence less precise prediction of ∆∆G
using the standard TIES protocol as mentioned in section 3.2 of the main article. In this
study, 5 out of the 16 transformations of MCL1 ligands have a charged carboxylate group in
the perturbing region, with the uncertainties of their ∆∆G predictions lying in the range of
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0.7-0.8 kcal/mol, while the uncertainties of the remaining 11 predictions for MCL1 ligands
lie within the range of 0.2-0.4 kcal/mol (see Table 1). In such cases, one can modify the
standard protocol described here by, for example, increasing the ensemble size at various
λ-windows and/or excluding the charged group from the alchemically mutating part of the
ligands to further emphasise this point. In the following paragraph we describe one such
case including a comparison of its results with and without charged groups in the perturbing
region of the ligand.
Figure S8: Two different conformations of the flexible carboxylate group of ligand L14 inside
the binding pocket of PTP1B taken from the same molecular dynamics simulation. Due
to three adjacent rotatable bonds through which the carboxylate group is attached to the
ligand, the corresponding dihedral angle changes substantially inside the binding pocket
when the electrostatic interactions are scaled to small values. The protein is shown in grey
ribbon and ligand atoms are colored by element; hydrogen in white, carbon in cyan, oxygen
in red and nitrogen in blue.
The ligands studied with PTP1B all have two carboxylate groups present in the active
site of the protein. One of them is attached to the thiophene ring through three rotatable
bonds and the binding pocket provides it with enough space to move around. Because of
this, the carboxylate group is highly flexible. Figure S8 shows a transformation (L6 to L14)
where this carboxylate group forms part of the perturbing region of the ligand within a
TIES calculation. Two different conformations of this flexible carboxylate group are shown
at an intermediate λ-window where the electrostatic interactions are scaled down to very
small values. It is clear that, in the absence of strong electrostatic interactions, such a
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charged group is highly flexible, leading to a diminution in both the accuracy and precision
of our predictions. In this case, ∆∆GTIES = 0.6 ± 1.7 kcal/mol while the corresponding
experimental value is -1.0 kcal/mol. This problem can be dealt with by excluding the charged
species from the perturbing region of the ligand. Performing the TIES calculation again for
this transformation, after excluding the carboxylate groups from the perturbing regions of
the ligand, substantially improves the accuracy and precision of our prediction, yielding a
new value of ∆∆GTIES = −0.8±0.4 kcal/mol very close to the experimental relative binding
affinity.
Figure S9: The generic structure of MCL1 ligands with the four membered linker joining the
two ends of the ligand containing different functional groups. One end of the ligand is bound
to the lower pocket (LP) of the protein and is relatively rigid, while the other end of the ligand
is bound to the upper pocket (UP) of the protein and is quite flexible. The carboxylate group
present at the second end of the ligand interacts with the side chain of the arginine residue
of the protein (R263). The protein surface is shown in grey, the arginine residue (R263) is
shown in colored electrostatic surface and ligand atoms are colored by element; hydrogen in
white, carbon in cyan, oxygen in red and nitrogen in blue. All non-polar hydrogens have
been excluded for clarity.
It is evident from Table 1 and Figure 5 in the main document that the TIES predictions
for MCL1 have larger deviations from the experimental results, with the largest RMSE and
MAE. Such behavior can be attributed to the highly flexible nature of the ligand. Figure
S9 shows the structure of one of the MCL1 ligands. Generically, they contain a 4-membered
linker which connects the two ends of the ligand. One end of the ligand is a hydrophobic
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aromatic system which is buried deep into the lower pocket (LP) of the protein (Figure S9).
Another end of the ligand is a 6,5-fused heterocyclic carboxylic acid which is held at the
upper pocket (UP) (Figure S9). The latter interacts with the positively charged side chain
of the arginine residue (R263). Since the linker chain has four rotatable bonds, the two
ends of the ligand are free to move with respect to each other. The end located in LP is
rigid as compared to the other end. Its interaction with R263 becomes too weak to hold
it in a stable position at intermediate λ-windows due to the scaling down of electrostatic
interactions. This accounts for why the least accurate results occur for the MCL1 predictions
as compared to the other targets.
Figure S10: A comparison between the 18 ligand transformations which are common between
the ones studied here and those studied by Wang et al. using their FEP methodology.S1
Results from the FEP methodology are shown on the left, while those from TIES are shown
on the right. TIES exhibits marginally better accuracy with slightly smaller RMSE and MAE
and slightly larger Pearson’s r and Spearman’s ρ. Only one of the 18 TIES predictions lies
outside the 1 kcal/mol window from the experimental data and one directionally disagrees
with the experimental value; the corresponding numbers for the FEP predictions are three
and two respectively.
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Table S6: Hysteresis in the TIES predictions for the closed cycles formed by the ligand
transformations studied.
Protein Ligands forming closed cycles Hysteresis (kcal/mol)
CDK2 L1Q,L20,L21 0.02
MCL1 L32,L42,L38 1.19
TYK2
L1,L6,L10,L15 0.01
L1,L6,L10 0.32
L1,L10,L15 0.31
L1,L15,L6 0.06
Figure S11: Variation of uncertainties in the TIES-predictions with the size of the pertur-
bation (measured in terms of the number of appearing or disappearing atoms) for the trans-
formations of ligands binding with PTP1B. In this case, and more generally, we observe no
clear dependence of the uncertainty on the size of the perturbation.
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